Compare TWST & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWST | HAE |
|---|---|---|
| Founded | 2013 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.8B |
| IPO Year | 2018 | 1996 |
| Metric | TWST | HAE |
|---|---|---|
| Price | $68.31 | $78.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $46.88 | ★ $84.13 |
| AVG Volume (30 Days) | ★ 1.5M | 930.6K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ 2.05 |
| Revenue | $376,572,000.00 | ★ $910,373,000.00 |
| Revenue This Year | $18.91 | N/A |
| Revenue Next Year | $15.07 | $5.23 |
| P/E Ratio | ★ N/A | $38.40 |
| Revenue Growth | ★ 20.32 | N/A |
| 52 Week Low | $23.30 | $47.32 |
| 52 Week High | $80.50 | $87.32 |
| Indicator | TWST | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 59.20 | 80.04 |
| Support Level | $41.85 | $48.98 |
| Resistance Level | N/A | $86.72 |
| Average True Range (ATR) | 5.06 | 2.89 |
| MACD | 0.37 | 1.46 |
| Stochastic Oscillator | 57.25 | 89.95 |
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.